Novo Nordisk's oral GLP-1/amylin dual agonist showing unprecedented weight loss for an oral medication.
Amycretin is an investigational oral peptide developed by Novo Nordisk that combines GLP-1 and amylin receptor agonism in a single molecule. It represents a convergence of two major trends in obesity medicine: dual-receptor targeting (like CagriSema) and oral delivery (like orforglipron).
Amylin is a hormone co-secreted with insulin that promotes satiety, slows gastric emptying, and suppresses glucagon. By combining amylin's mechanisms with GLP-1's powerful appetite suppression and insulin sensitization, amycretin targets multiple metabolic pathways simultaneously. The oral formulation would eliminate the need for injections entirely.
Early clinical data has generated significant excitement: amycretin showed up to 13% weight loss in just 12 weeks in Phase 1 — a rate of weight loss that, if sustained, could rival or exceed injectable agents.
Phase 1 results presented at conferences showed remarkable weight loss velocity: up to 13% body weight reduction over 12 weeks with oral amycretin. This exceeds the early weight loss trajectory of injectable semaglutide and tirzepatide at comparable time points.
The dual GLP-1/amylin mechanism in oral form is unique. If Phase 2/3 data confirms the Phase 1 trajectory, amycretin could become a game-changing oral obesity treatment. Novo Nordisk has prioritized its development.
GI side effects expected (nausea, vomiting). Full safety profile not yet established. Clinical trial use only.
NOT FDA-approved. In Phase 1/2 clinical trials. Novo Nordisk pipeline.